Clinically feasible approaches to potentiating cancer cell-based immunotherapies. - Wikidata - awgldk - TriplyDB

Clinically feasible approaches to potentiating cancer cell-based immunotherapies.

Clinically feasible approaches to potentiating cancer cell-based immunotherapies.

http://www.wikidata.org/entity/Q38453610

about

Endothelial Dysfunction and Inflammation: Immunity in Rheumatoid Arthritis Novel role of granulocyte-macrophage colony-stimulating factor: antitumor effects through inhibition of epithelial-to-mesenchymal transition in esophageal cancer.Immune adjuvant effect of a Toxoplasma gondii profilin-like protein in autologous whole-tumor-cell vaccination in mice.Elevated serum granulocyte-macrophage colony-stimulating factor levels during radiotherapy predict favorable outcomes in lung and esophageal cancer.Mesothelin-targeting chimeric antigen receptor-modified T cells by piggyBac transposon system suppress the growth of bile duct carcinoma.A Possible Role for Idiotype/Anti-idiotype B-T Cell Interactions in Maintaining Immune Memory.Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients.Immunomodulation by ionizing radiation-impact for design of radio-immunotherapies and for treatment of inflammatory diseases.Differential Role of B Cells and IL-17 Versus IFN-γ During Early and Late Rejection of Pig Islet Xenografts in Mice.Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells.

P2860

Q26749294-5CBDDF39-3E9B-4DCB-9E7A-5F95CBF86220 Q33602583-ECC1D3B1-0E54-41E4-8DCA-5BF06EE65141 Q37687530-D34C487D-EA6D-446E-B0F8-89F105962495 Q37709102-90AE70AA-743A-41AD-BE8B-9520B3527DA1 Q40256333-C6BAC5B5-FF57-4EF5-BF07-966C3E5D7DA7 Q41973429-5056102F-50CD-4DF8-9816-FB3718A8BC7F Q47141906-93E2F625-F8AC-4E84-910F-FF1F53ED19AF Q48193685-7A3E4975-1CB6-45BC-A775-176D11E17AAA Q51040316-17678A84-D356-4768-A87E-EF5D73F3C31B Q52657140-C35BBDF7-D024-4A4A-8750-D4B96A614F9F

P2860

Clinically feasible approaches to potentiating cancer cell-based immunotherapies.

http://www.wikidata.org/entity/Q38453610

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Clinically feasible approaches to potentiating cancer cell-based immunotherapies.

@en

type

label

Clinically feasible approaches to potentiating cancer cell-based immunotherapies.

@en

prefLabel

Clinically feasible approaches to potentiating cancer cell-based immunotherapies.

@en

P1433

Q38453610-A6D5685B-2BBC-4B8D-AB7C-CF1817DF98DF

P1476

Q38453610-58CC99BD-9F52-4AB5-9C85-FF4CA9AF2995

P2093

Q38453610-5D223B01-479E-458A-A3D9-A5E371924DAF

Q38453610-911CA93B-6AA6-481F-A119-DE2EAA56196E

Q38453610-A597F00D-A883-4A79-8BDD-47D10BD50BF2

P2860

Q38453610-01980FFA-A97F-4B96-ACEE-9E320EA9332F

Q38453610-01D898DF-05D6-4CC9-9448-3DAC094ABE50

Q38453610-04391A60-EA0F-4483-9E8E-C1620FD43897

Q38453610-061A688E-0CE9-4449-B205-AA861C85B441

Q38453610-0749B3FC-09D9-4661-BD85-B462BEFAF733

Q38453610-0827205A-A60D-41E0-8E5D-650BEF5ABBF0

Q38453610-09CE2CD8-744D-4019-8618-AC376916EBEF

Q38453610-0CEDC993-C658-4760-A31B-2F74C5E31328

Q38453610-0F9947E7-0881-4818-86A0-4C68EFB40D6C

Q38453610-11374AFD-CF9A-494A-9E81-75A165CEAFC6

P304

Q38453610-D22CA106-4521-470C-BD27-D62CB833424D

P31

Q38453610-BA5A29D3-92BB-46F8-B93D-E992D2C77492

P356

Q38453610-624D614B-C179-4438-8E94-8B161B4F7D3B

P433

Q38453610-0E47EFEF-3406-4BCF-A1F1-35F68F5C222D

P478

Q38453610-0E571EAA-49D3-4ABB-9170-20F71930E87A

P50

Q38453610-C4C22A10-53BF-4950-B20E-F377873CEC40

Q38453610-E0784F61-308E-4987-A031-6120EC164A48

Q38453610-FB12F959-6531-4006-9411-D772FFC9985B

P577

Q38453610-04D06CEA-CE42-4DC6-8600-3BC55C753BD2

P698

Q38453610-9429061F-A62F-4D8D-9D1D-7662010F7A9C

P932

Q38453610-DA1A7BD2-5099-43A7-A964-F044F40FBDDB

P356

21645515.2015.1009814

P1433

Human Vaccines & Immunotherapeutics

P1476

Clinically feasible approaches to potentiating cancer cell-based immunotherapies

@en

P2093

A G Goncharov

http://www.w3.org/2001/XMLSchema#string

G V Seledtsova

http://www.w3.org/2001/XMLSchema#string

V I Seledtsov

http://www.w3.org/2001/XMLSchema#string

P2860

Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Pathogen recognition and inflammatory signaling in innate immune defenses

Therapeutic cancer vaccines: past, present, and future

Immunotherapeutic approach for better management of cancer--role of IL-18

Innate and adaptive immune cells in the tumor microenvironment

Cancer immunotherapy

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta

P304

851-869

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/21645515.2015.1009814

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Victor I. Seledtsov

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25933181

http://www.w3.org/2001/XMLSchema#string

P932

4514272

http://www.w3.org/2001/XMLSchema#string